Dexcom 

$67.85
351
-$0.67-0.97% Wednesday 17:44

统计数据

当日最高
68.71
当日最低
66.88
52周最高
138.89
52周最低
66.88
成交量
2,801
平均成交量
2,732
市值
-
市盈率
-
股息收益率
-
股息
-

即将到来

收益

24Oct预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
0.14
0.26
0.38
0.5
预期每股收益
0.435055
实际每股收益
N/A

人们还关注

此列表基于关注0A4M.LSE的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
Abbott Laboratories
ABT
市值197.08B
Abbott Laboratories在连续血糖监测(CGM)市场上与Dexcom竞争,尤其是他们的FreeStyle Libre系统。
Medtronic
MDT
市值113.61B
美敦力是CGM和糖尿病管理市场上的直接竞争对手,提供Guardian Connect系统等产品。
Tandem Diabetes Care
TNDM
市值2.85B
Tandem Diabetes Care与Dexcom合作进行CGM集成,但也在提供全面的糖尿病管理解决方案方面竞争。
Insulet
PODD
市值14.22B
Insulet Corporation的Omnipod系统是糖尿病管理领域的竞争对手,为传统胰岛素输送和监测系统提供了一种替代方案。
Senseonics
SENS
市值208.39M
Senseonics Holdings提供Eversense CGM系统,提供长期可植入的葡萄糖监测,是Dexcom可穿戴式CGM产品的直接竞争对手。
Novo Nordisk
NVO
市值620.4B
诺和诺德通过其广泛的糖尿病护理产品间接竞争,包括胰岛素和非胰岛素治疗,这些产品是综合糖尿病管理的一部分。
Sanofi
SNY
市值141.43B
Sanofi通过其胰岛素和血糖监测解决方案在糖尿病市场上与Dexcom的CGM系统竞争,为用户提供了另一种选择。
Mckesson
MCK
市值72.76B
麦克森公司通过分销包括CGM在内的糖尿病护理产品,在更广泛的糖尿病管理解决方案市场上竞争。
Cardinal Health
CAH
市值27.49B
Cardinal Health参与了各种医疗保健产品的分销,包括糖尿病护理用品,在更广泛的糖尿病管理市场上竞争。
AMERISOURCEBERGEN CORP
ABC
市值34.08B
美源伯根公司通过分销药品和医疗保健产品(包括糖尿病护理技术)进行竞争,影响整体市场格局。

关于

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
首席执行官
Kevin Sayer
员工
9500
国家
US
ISIN
US2521311074

上市公司